Viracta Therapeutics Inc. (NASDAQ: VIRX)
$0.56
+0.0242 ( +4.56% ) 108.3K
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Market Data
Open
$0.56
Previous close
$0.53
Volume
108.3K
Market cap
$21.91M
Day range
$0.53 - $0.57
52 week range
$0.43 - $1.68
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Feb 27, 2024 |
4 | Insider transactions | 1 | Dec 04, 2023 |
4 | Insider transactions | 1 | Nov 28, 2023 |
4 | Insider transactions | 1 | Nov 28, 2023 |
4 | Insider transactions | 1 | Nov 28, 2023 |
8-k | 8K-related | 12 | Nov 17, 2023 |
10-q | Quarterly Reports | 52 | Nov 09, 2023 |
8-k | 8K-related | 13 | Nov 09, 2023 |
8-k | 8K-related | 62 | Oct 04, 2023 |
4 | Insider transactions | 1 | Aug 29, 2023 |